Microencapsulated Vaccinium floribundum Kunth extract promotes angiogenesis and attenuates inflammation in in vitro and in vivo models.

Natural products, especially polyphenol-rich medicinal plants, are increasingly investigated as multitarget therapeutics in both human and veterinary medicine for angiogenic regenerative properties and for inflammation based-diseases. Recent developments in natural product formulation, notably microencapsulation, have been shown to improve the stability, bioavailability, and controlled release of bioactive compounds. The integration of complementary in vitro and in vivo models is critical for evaluating both efficacy and translational potential. In this context, the present study assessed the phytochemical composition and biological activity of a microencapsulated Ecuadorian Vaccinium floribundum extract (VFM), using a combination of in vitro and in vivo approaches. VFM biochemical characterization identified 15 compounds, including flavonoids, procyanidins, dihydrochalcones, and phenolic acids, with chlorogenic acid and quercetin as the most abundant metabolites. Anthocyanins ideain and petunidin were also detected, confirming a rich bioactive profile. Primary porcine thoracic aortic endothelial cells (pAECs) were treated with VFM to assess cell viability and angiogenic potential and challenged with bacterial lipopolysaccharide (LPS) in the presence or absence of the extract. Anti-inflammatory effects were further evaluated in vivo using a carrageenan-induced mouse paw edema model. VFM enhanced endothelial cell viability, promoted capillary-like network and modulated early angiogenic signaling pathways. It mitigated LPS-induced endothelial dysfunction by reducing pro-inflammatory cytokines and oxidative stress markers. In vivo, paw edema assays confirmed its anti-inflammatory efficacy, with microencapsulation likely sustaining bioactive release. These findings support the traditional use of Vaccinium floribundum and highlight its potential for developing nutraceutical formulations targeting vascular and inflammatory disorders.